Mitsubishi Tanabe Pharma Corporation

Astrazeneca Ab

Shigeki Sakamaki

Sumihiro Nomura

Masakazu Fujio

Kenneth Lars Granberg

Yasuki Niwa

Stig Jonas Boström

Hans Fredrik Bergström

Ryuichi Fuchigami

The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R, R, R, Rand Rhave the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.

Compounds and their use

Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein Ris fluorine, or chlorine, and Ris hydrogen, or fluorine, which are SGLT inhibitors and are useful for treatment or prevention of diabetes and related conditions.

Indole derivatives

Growing community of inventors

Osaka, Japan

Shigeki Sakamaki